维瑞努拉德加艾洛普诺尔治疗心力衰竭与保存的喷射小部分:AMETHYST随机临床试验
Dalane W Kitzman1, Adriaan A Voors2, Robert J Mentz3
1Department of Internal Medicine, Sections on Cardiovascular Medicine and Geriatrics, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
JAMA cardiology
|August 14, 2024
概括
这项研究发现,在患有心力衰竭和保留喷射分数 (HFpEF) 的患者中,乙氨酸加罗醇有效降低了血清尿酸 (SUA). 然而,与安慰剂相比,它没有改善运动能力或症状.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 血清尿酸 (SUA) 的升高与内皮功能障碍有关,并且可能是心力衰竭治疗的治疗标,其中保留了喷射分数 (HFpEF).
- 没有先前的随机临床试验专门研究了HFpEF患者的SUA降低.
研究的目的:
- 为了评估Verginurad的疗效和安全性,一种新型的尿酸载体-1抑制剂,在被诊断为HFpEF和升高的SUA水平的患者中.
- 评估与氨醇结合的氨酸对HFpEF运动能力,症状和安全结果的影响.
主要方法:
- 一个第二阶段,双盲,随机临床试验,涉及159名HFpEF和SUA>6mg/dL的患者.
- 患者接受了verginurad加Allopurinol,Allopurinol单一治疗或安慰剂24周,最初12周接受了.
- 主要终点包括峰值氧气吸收 (VO2) 的变化,堪萨斯城心肌病问卷总症状得分 (KCCQ-TSS) 和32周的SUA水平.
主要成果:
- 与单独的阿洛普林醇 (-37.6%) 或安慰剂 (0.8%) (P < .001) 相比,维瑞努拉德加上阿洛普林醇显著降低了59.6%的SUA水平.
- 在治疗组之间,在峰值VO2或KCCQ-TSS变化中没有观察到显著差异.
- 没有检测到任何不良安全信号,两组心血管事件和死亡率相似.
结论:
- 虽然vereninurad有效地降低了HFpEF患者的SUA,但这种降低并没有转化为运动能力或症状得分的显著改善.
- 需要进一步的研究来确定SUA降低在HFpEF管理中的临床相关性.
- 瓦尼努拉德和阿洛普林醇的组合在这个患者群体中显示出有利的安全性.
相关概念视频
Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Renal Failure: Dose Adjustments
71
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
71
Heart Failure Drugs: β-Blockers
324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324
Heart Failure Drugs: Inotropic Agents
547
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
547
Antihypertensive Drugs: Potassium-Sparing Diuretics
482
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
482


